Oral Cannabis for Secondary Prevention of Chemotherapy-Induced Nausea and Vomiting
The final results of the study on Oral Cannabis Extract for the secondary prevention of chemotherapy-induced nausea and vomiting were recently published in the Journal of Clinical Oncology.
Doctors shared their insights regarding the study on social media:
Elizabeth Prsic (Medical Oncology Firm Chief at Smilow Cancer Hospital):
“Oral Cannabis for Secondary Prevention of Chemotherapy-Induced Nausea and Vomiting: A Randomized, Placebo-Controlled, Phase II/III Trial.
Given 1/3 of patients with advanced cancer use for symptom support, wonderful to see more research being done!”
Katy Moore (Senior Scientific Officer at the Institute of Cancer Research):
“Thanks Ryan Nipp boosting this randomized trial of oral cannabis extract for CINV– yes it works but at cost of other adverse events.
This work provides science driven data to better counsel and support patient on treatment. Impressed!”
Ryan Nipp (Cancer Outcomes Researcher at the University of Oklahoma):
“Oral Cannabis Extract for Secondary Prevention of Chemotherapy-Induced Nausea and Vomiting: Final Results of a Randomized, Placebo-Controlled, Phase II/III Trial.”
Authors: Peter Grimison, Antony Mersiades, Adrienne Kirby, Annette Tognela, Ian Olver, Rachael L. Morton, Paul Haber, Anna Walsh, Yvonne Lee, Ehtesham Abdi, Stephen Della-Fiorentina, Morteza Aghmesheh, Peter Fox, Karen Briscoe, Jasotha Sanmugarajah, Gavin Marx, Ganessan Kichenadasse, Helen Wheeler, Matthew Chan, Jenny Shannon, Craig Gedye, Stephen Begbie, R. John Simes, Martin R. Stockler.
For more posts like this, visit oncodaily.com.
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023